Mineralocorticoid Receptor Antagonists
The role and adverse effects of mineralocorticoid receptor overactivation in the pathophysiology of heart failure (HF) is wellrecognised. MR antagonists (MRAs) have been tested in HF and shown to be effective in improving outcomes. Steroid-type MRAs spironolactone and eplerenone, have been proven to...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Barcaray International
2019-01-01
|
Series: | International Cardiovascular Forum Journal |
Subjects: | |
Online Access: | https://icfjournal.org/index.php/icfj/article/view/603/pdf |
id |
doaj-848580effa6e45b8b6b1356181b43207 |
---|---|
record_format |
Article |
spelling |
doaj-848580effa6e45b8b6b1356181b432072020-11-25T03:57:04ZengBarcaray InternationalInternational Cardiovascular Forum Journal2410-26362409-34242019-01-01173436https://doi.org/10.17987/icfj.v17i0.603Mineralocorticoid Receptor AntagonistsIlaria Spoletini0Giuseppe MC Rosano1IRCCS San Raffaele Pisana, ItalyCentre for Clinical & Basic Research IRCCS San Raffaele Pisana, via della Pisana, 235, 00163 Rome, ItalyThe role and adverse effects of mineralocorticoid receptor overactivation in the pathophysiology of heart failure (HF) is wellrecognised. MR antagonists (MRAs) have been tested in HF and shown to be effective in improving outcomes. Steroid-type MRAs spironolactone and eplerenone, have been proven to reduce mortality in HFrEF. In patients with HFpEF, the TOPCAT trial found no significant benefits of spironolactone on cardiovascular outcomes. In order to overcome the limitations of existing steroidal MRAs, novel MRAs have been recently developed, finerenone and PF-03882845. These newer agents aim to optimise the benefits of MRAs and reduce their side-effects, especially hyperkalaemia.https://icfjournal.org/index.php/icfj/article/view/603/pdfheart failuremineralocorticoid receptor antagonists |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ilaria Spoletini Giuseppe MC Rosano |
spellingShingle |
Ilaria Spoletini Giuseppe MC Rosano Mineralocorticoid Receptor Antagonists International Cardiovascular Forum Journal heart failure mineralocorticoid receptor antagonists |
author_facet |
Ilaria Spoletini Giuseppe MC Rosano |
author_sort |
Ilaria Spoletini |
title |
Mineralocorticoid Receptor Antagonists |
title_short |
Mineralocorticoid Receptor Antagonists |
title_full |
Mineralocorticoid Receptor Antagonists |
title_fullStr |
Mineralocorticoid Receptor Antagonists |
title_full_unstemmed |
Mineralocorticoid Receptor Antagonists |
title_sort |
mineralocorticoid receptor antagonists |
publisher |
Barcaray International |
series |
International Cardiovascular Forum Journal |
issn |
2410-2636 2409-3424 |
publishDate |
2019-01-01 |
description |
The role and adverse effects of mineralocorticoid receptor overactivation in the pathophysiology of heart failure (HF) is wellrecognised. MR antagonists (MRAs) have been tested in HF and shown to be effective in improving outcomes. Steroid-type MRAs spironolactone and eplerenone, have been proven to reduce mortality in HFrEF. In patients with HFpEF, the TOPCAT trial found no significant benefits of spironolactone on cardiovascular outcomes. In order to overcome the limitations of existing steroidal MRAs, novel MRAs have been recently developed, finerenone and PF-03882845. These newer agents aim to optimise the benefits of MRAs and reduce their side-effects, especially hyperkalaemia. |
topic |
heart failure mineralocorticoid receptor antagonists |
url |
https://icfjournal.org/index.php/icfj/article/view/603/pdf |
work_keys_str_mv |
AT ilariaspoletini mineralocorticoidreceptorantagonists AT giuseppemcrosano mineralocorticoidreceptorantagonists |
_version_ |
1724462168429035520 |